The approval allows the company to market Imfinzi 120 mg/2.4 ml and 500 mg/10 ml in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment post-radical cystectomy. Shares of Astrazeneca Pharma India Ltd ended at ₹9,171.40, down by ₹65.65, or 0.71%, on the BSE.
